A carregar...
Potential for Long‐Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA‐Mutated Advanced Breast Cancer
Alpelisib plus fulvestrant provides long‐term disease control in patients with endocrine‐resistant, HR‐positive, HER2‐negative, PIK3CA‐mutated advanced breast cancer, according to an updated analysis from the SOLAR‐1 and X2101 trials.
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262312/ https://ncbi.nlm.nih.gov/pubmed/34173298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13873 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|